Andere Sprachen 4D Molecular Therapeutics, Inc.

Aktien

A2PS5P

US35104E1001

FDMT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
23.25 ^USD	-1.19%		-7.92%	+14.76%

15.04.	4D MOLECULAR THERAPEUTICS, INC. : Barclays bleibt bei seiner Kaufempfehlung	ZM
15.04.	4D MOLECULAR THERAPEUTICS, INC. : RBC Capital Markets behält die Bewertung Kaufen bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	07.04.
Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	07.04.
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	07.04.
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024.	07.04.
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	04.04.
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis	28.03.
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	28.03.
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	28.03.
4DMT to Participate in Upcoming Investor Conferences	04.03.
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
4DMT Reports Full Year 2023 Financial Results and Operational Highlights	29.02.
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024	12.02.
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024	12.02.
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024	12.02.
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing	08.02.
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock	07.02.
4D Molecular Therapeutics Launches $250 Million Stock Offering	05.02.
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock	05.02.
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock	05.02.
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate	05.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen 4D Molecular Therapeutics, Inc.

Aktien

A2PS5P

US35104E1001

FDMT

Andere Sprachen

Filter